Carbonic anhydrases (CAs) catalyze the hydration of CO(2) forming HCO(3)(-) and a proton, an important reaction for many physiological processes including respiration, fluid secretion, and pH regulation. As such, CA isoforms are prominent clinical targets for treating various diseases. The clinically used acetazolamide (AZM) is a sulfonamide that binds with high affinity to human CA isoform II (HCA II). There are several X-ray structures available of AZM bound to various CA isoforms, but these complexes do not show the charged state of AZM or the hydrogen atom positions of the protein and solvent. Neutron diffraction is a useful technique for directly observing H atoms and the mapping of H-bonding networks that can greatly contribute to rational drug design. To this end, the neutron structure of H/D exchanged HCA II crystals in complex with AZM was determined. The structure reveals the molecular details of AZM binding and the charged state of the bound drug. This represents the first determined neutron structure of a clinically used drug bound to its target.
Carbonic anhydrases (CAs) catalyze the hydration of CO(2) forming n class="Chemical">HCO(3)(-) and a proton, an important reaction for many physiological processes including respiration, fluid secretion, and pH regulation. As such, CA isoforms are prominent clinical targets for treating various diseases. The clinically used acetazolamide (AZM) is a sulfonamide that binds with high affinity to human CA isoform II (HCA II). There are several X-ray structures available of AZM bound to various CA isoforms, but these complexes do not show the charged state of AZM or the hydrogen atom positions of the protein and solvent. Neutron diffraction is a useful technique for directly observing H atoms and the mapping of H-bonding networks that can greatly contribute to rational drug design. To this end, the neutron structure of H/D exchanged HCA II crystals in complex with AZM was determined. The structure reveals the molecular details of AZM binding and the charged state of the bound drug. This represents the first determined neutron structure of a clinically used drug bound to its target.
Authors: Anna S Gardberg; Alexis Rae Del Castillo; Kevin L Weiss; Flora Meilleur; Matthew P Blakeley; Dean A A Myles Journal: Acta Crystallogr D Biol Crystallogr Date: 2010-04-21
Authors: Brad Bennett; Paul Langan; Leighton Coates; Marat Mustyakimov; Benno Schoenborn; Elizabeth E Howell; Chris Dealwis Journal: Proc Natl Acad Sci U S A Date: 2006-11-27 Impact factor: 11.205
Authors: Katherine H Sippel; Arthur H Robbins; John Domsic; Caroli Genis; Mavis Agbandje-McKenna; Robert McKenna Journal: Acta Crystallogr Sect F Struct Biol Cryst Commun Date: 2009-09-25
Authors: Mayank Aggarwal; Christopher D Boone; Bhargav Kondeti; Chingkuang Tu; David N Silverman; Robert McKenna Journal: Acta Crystallogr D Biol Crystallogr Date: 2013-04-19